Chitosan solution enhances the immunoadjuvant properties of GM-CSF

Vaccine

Volumn 25, Issue 52, 2007, Pages 8673-8686

  Zaharoff, David A ^a   Rogers, Connie J ^a   Hance, Kenneth W ^a   Schlom, Jeffrey ^a   Greiner, John W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chitosan; Controlled release; Cytokine; GM CSF; Immunoadjuvant

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHITOSAN; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BIOCOMPATIBILITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; INGUINAL LYMPH NODE; INJECTION SITE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHITOSAN; CYTOTOXICITY TESTS, IMMUNOLOGIC; DELAYED-ACTION PREPARATIONS; DENDRITIC CELLS; FEMALE; GENE EXPRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS II; INJECTIONS, SUBCUTANEOUS; LYMPH NODES; LYMPHOCYTE SUBSETS; MICE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 36549067721     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.037     Document Type: Article

References (57)

1. Gulley J.L., Arlen P.M., Bastian A., Morin S., Marte J., Beetham P., et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11 9 (2005) 3353-3362
2. Marshall J.L., Gulley J.L., Arlen P.M., Beetham P.K., Tsang K.Y., Slack R., et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23 4 (2005) 720-731
3. Tarr P.E., Lin R., Mueller E.A., Kovarik J.M., Guillaume M., and Jones T.C. Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine. Vaccine 14 13 (1996) 1199-1204
4. Leong S.P., Enders-Zohr P., Zhou Y.M., Stuntebeck S., Habib F.A., Allen Jr. R.E., et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 22 2 (1999) 166-174
5. Kass E., Panicali D.L., Mazzara G., Schlom J., and Greiner J.W. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 61 1 (2001) 206-214
6. Reali E., Canter D., Zeytin H., Schlom J., and Greiner J.W. Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine 23 22 (2005) 2909-2921
7. Disis M.L., Bernhard H., Shiota F.M., Hand S.L., Gralow J.R., Huseby E.S., et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88 1 (1996) 202-210
8. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., and Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13 3 (1995) 688-696
9. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271 12 (1994) 907-913
10. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90 7 (1997) 2541-2548
11. Burgess A.W., and Metcalf D. The nature and action of granulocyte-macrophage colony stimulating factors. Blood 56 6 (1980) 947-958
12. Kass E., Parker J., Schlom J., and Greiner J.W. Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes. Cytokine 12 7 (2000) 960-971
13. Kremer I.B., Stevens S.R., Gould J.W., DiCarlo J., Quinby G.E., and Cooper K.D. Intradermal granulocyte-macrophage colony-stimulating factor alters cutaneous antigen-presenting cells and differentially affects local versus distant immunization in humans. Clin Immunol 96 1 (2000) 29-37
14. Morrissey P.J., Bressler L., Park L.S., Alpert A., and Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 139 4 (1987) 1113-1119
15. Jager E., Ringhoffer M., Dienes H.P., Arand M., Karbach J., Jager D., et al. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67 1 (1996) 54-62
16. Kwak L.W., Young H.A., Pennington R.W., and Weeks S.D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci USA 93 20 (1996) 10972-10977
17. Song R., Liu S., Adams R.J., and Leong K.W. Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models. J Interferon Cytokine Res 26 6 (2006) 380-389
18. van Slooten M.L., Storm G., Zoephel A., Kupcu Z., Boerman O., Crommelin D.J., et al. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines. Pharm Res 17 1 (2000) 42-48
19. Nair R.E., Jong Y.S., Jones S.A., Sharma A., Mathiowitz E., and Egilmez N.K. IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J Immunother 29 1 (2006) 10-20
20. Hege K.M., Jooss K., and Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 25 5-6 (2006) 321-352
21. Thomas T.T., Kohane D.S., Wang A., and Langer R. Microparticulate formulations for the controlled release of interleukin-2. J Pharm Sci 93 5 (2004) 1100-1109
22. Hanes J., Sills A., Zhao Z., Suh K.W., Tyler B., DiMeco F., et al. Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors. Pharm Res 18 7 (2001) 899-906
23. Egilmez N.K., Jong Y.S., Hess S.D., Jacob J.S., Mathiowitz E., and Bankert R.B. Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID-Winn model. J Immunother 23 2 (2000) 190-195
24. Pettit D.K., Lawter J.R., Huang W.J., Pankey S.C., Nightlinger N.S., Lynch D.H., et al. Characterization of poly(glycolide-co-D,L-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF. Pharm Res 14 10 (1997) 1422-1430
25. Sharma A., Harper C.M., Hammer L., Nair R.E., Mathiowitz E., and Egilmez N.K. Characterization of cytokine-encapsulated controlled-release microsphere adjuvants. Cancer Biother Radiopharm 19 6 (2004) 764-769
26. Golumbek P.T., Azhari R., Jaffee E.M., Levitsky H.I., Lazenby A., Leong K., et al. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 53 24 (1993) 5841-5844
27. Holland T.A., Tabata Y., and Mikos A.G. In vitro release of transforming growth factor-beta 1 from gelatin microparticles encapsulated in biodegradable, injectable oligo(poly(ethylene glycol) fumarate) hydrogels. J Control Release 91 3 (2003) 299-313
28. Ozbas-Turan S., Akbuga J., and Aral C. Controlled release of interleukin-2 from chitosan microspheres. J Pharm Sci 91 5 (2002) 1245-1251
29. Sanchez A., Tobio M., Gonzalez L., Fabra A., and Alonso M.J. Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. Eur J Pharm Sci 18 3-4 (2003) 221-229
30. Broderick L., Yokota S.J., Reineke J., Mathiowitz E., Stewart C.C., Barcos M., et al. Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells. J Immunol 174 2 (2005) 898-906
31. Sabel M.S., Skitzki J., Stoolman L., Egilmez N.K., Mathiowitz E., Bailey N., et al. Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity. Ann Surg Oncol 11 2 (2004) 147-156
32. Kilinc M.O., Aulakh K.S., Nair R.E., Jones S.A., Alard P., Kosiewicz M.M., et al. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 177 10 (2006) 6962-6973
33. Arora A., Su G., Mathiowitz E., Reineke J., Chang A.E., and Sabel M.S. Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity. J Surg Oncol 94 5 (2006) 403-412
34. Bartus R.T., Tracy M.A., Emerich D.F., and Zale S.E. Sustained delivery of proteins for novel therapeutic agents. Science 281 5380 (1998) 1161-1162
35. van de Weert M., Hennink W.E., and Jiskoot W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 17 10 (2000) 1159-1167
36. Fu K., Pack D.W., Klibanov A.M., and Langer R. Visual evidence of acidic environment within degrading poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res 17 1 (2000) 100-106
37. Vyas S.P., Rawat M., Rawat A., Mahor S., and Gupta P.N. Pegylated protein encapsulated multivesicular liposomes: a novel approach for sustained release of interferon alpha. Drug Dev Ind Pharm 32 6 (2006) 699-707
38. Anderson P.M., Hanson D.C., Hasz D.E., Halet M.R., Blazar B.R., and Ochoa A.C. Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-gamma. Cytokine 6 1 (1994) 92-101
39. Koppenhagen F.J., Kupcu Z., Wallner G., Crommelin D.J., Wagner E., Storm G., et al. Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells. Clin Cancer Res 4 8 (1998) 1881-1886
40. Krup O.C., Kroll I., Bose G., and Falkenberg F.W. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. J Immunother 22 6 (1999) 525-538
41. van Slooten M.L., Hayon I., Babai I., Zakay-Rones Z., Wagner E., Storm G., et al. Immunoadjuvant activity of interferon-gamma-liposomes co-administered with influenza vaccines. Biochim Biophys Acta 1531 1-2 (2001) 99-110
42. Kanaoka E., Takahashi K., Yoshikawa T., Jizomoto H., Nishihara Y., and Hirano K. Continuous release of interleukin-2 from liposomal IL-2 (mixture of interleukin-2 and liposomes) after subcutaneous administration to mice. Drug Dev Ind Pharm 29 10 (2003) 1149-1153
43. Laverman P., Boerman O.C., Oyen W.J.G., Corstens F.H.M., and Storm G. In vivo applications of PEG liposomes: unexpected observations. Crit Rev Ther Drug Carrier Syst 18 6 (2001) 551-566
44. Zhao Z., and Leong K.W. Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci 85 12 (1996) 1261-1270
45. Zaharoff D.A., Rogers C.J., Hance K.W., Schlom J., and Greiner J.W. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 25 11 (2007) 2085-2094
46. Singla A.K., and Chawla M. Chitosan: some pharmaceutical and biological aspects--an update. J Pharm Pharmacol 53 8 (2001) 1047-1067
47. Mhurchu C.N., Dunshea-Mooij C., Bennett D., and Rodgers A. Effect of chitosan on weight loss in overweight and obese individuals: a systematic review of randomized controlled trials. Obes Rev 6 1 (2005) 35-42
48. Pittler M.H., and Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr 79 4 (2004) 529-536
49. Read R.C., Naylor S.C., Potter C.W., Bond J., Jabbal-Gill I., Fisher A., et al. Effective nasal influenza vaccine delivery using chitosan. Vaccine 23 35 (2005) 4367-4374
50. Mills K.H., Cosgrove C., McNeela E.A., Sexton A., Giemza R., Jabbal-Gill I., et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun 71 2 (2003) 726-732
51. McNeela E.A., Jabbal-Gill I., Illum L., Pizza M., Rappuoli R., Podda A., et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22 8 (2004) 909-914
52. Wedmore I., McManus J.G., Pusateri A.E., and Holcomb J.B. A special report on the chitosan-based hemostatic dressing: experience in current combat operations. J Trauma 60 3 (2006) 655-658
53. Al-Daccak R., Mooney N., and Charron D. MHC class II signaling in antigen-presenting cells. Curr Opin Immunol 16 1 (2004) 108-113
54. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M.P., and Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18 2 (2007) 226-232
55. Bronte V., Chappell D.B., Apolloni E., Cabrelle A., Wang M., Hwu P., et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 162 10 (1999) 5728-5737
56. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., and Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64 17 (2004) 6337-6343
57. Heer A.K., Shamshiev A., Donda A., Uematsu S., Akira S., Kopf M., et al. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J Immunol 178 4 (2007) 2182-2191